Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Open-Label Study Exploring a Simplified Kaletra (Lopinavir/Ritonavir)-Based Therapy Versus a Sustiva (Efavirenz)-Based Standard of Care in Previously Non-Treated HIV-Infected Subjects

Next Previous
X
Search
Trial Profile

A Randomized, Open-Label Study Exploring a Simplified Kaletra (Lopinavir/Ritonavir)-Based Therapy Versus a Sustiva (Efavirenz)-Based Standard of Care in Previously Non-Treated HIV-Infected Subjects

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 17 Sep 2009

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lopinavir/ritonavir (Primary) ; Efavirenz; Lamivudine/zidovudine
  • Indications HIV-1 infections
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Abbott Laboratories

    • Most Recent Events

    • 15 Aug 2009 Tolerability results, with respect to drug-induced osteoporosis, have been reported in the Journal of Acquired Immune Deficiency Syndromes.
    • 01 Mar 2009 Results published in AIDS Research and Human Retroviruses.
    • 15 Jul 2008 Primary endpoint results published in The Journal of Infectious Diseases in July 2008

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top